

A randomized study to establish the effects of spirulina in type 2 diabetes mellitus patients*

Eun Hee Lee¹, Ji-Eun Park¹, Young-Ju Choi², Kap-Bum Huh² and Wha-Young Kim^{1§}

¹Department of Nutritional Science and Food Management, Ewha Womans University, 11-1 Daehyeon-dong, Seodaemun-gu, Seoul 120-750, Korea

²21C Diabetics and Vascular Research Center, 40-19 Nogosan-dong, Mapo-gu, Seoul 121-806, Korea

Received September 25, 2008, Revised October 23, 2008, Accepted November 10, 2008

Abstract

Spirulina is a microscopic and filamentous cyanobacterium that contains essential amino acids, essential fatty acids, vitamins, minerals and anti-oxidative components. The purpose of this study was to examine effects of spirulina intervention in Korean patients with type 2 diabetes. The subjects were 37 type 2 diabetic patients who visited a diabetic clinic in Seoul and randomly assigned into spirulina (8 g/day) or control group. During the intervention period of 12 weeks, subjects were asked to keep usual diet and prohibited to take any functional foods or dietary supplements. Spirulina supplementation for 12 weeks did not affect anthropometric parameters, however, lowered plasma triglycerides level significantly ($p < 0.05$). Spirulina supplementation also resulted in a significant reduction in plasma malondialdehyde level ($p < 0.05$) and an increase in plasma adiponectin level ($p < 0.1$). The lipid lowering effect of spirulina supplementation was different according to serum lipid levels of the subjects before entering the intervention. The subjects with higher initial triglyceride level showed higher reduction in plasma triglyceride and blood pressure. The subjects with higher initial total cholesterol and LDL-cholesterol level showed higher reduction in plasma concentrations of total cholesterol, LDL-cholesterol, IL-6, and blood pressure. It seems that spirulina supplementation is more effective in subjects with dyslipidemia. This study provides the evidence for beneficial effects of spirulina supplementation on blood lipid profiles, inflammatory variables, and antioxidant capacity in Korean patients with type 2 diabetes. The results suggest that spirulina is a promising agent as a functional food for diabetes management.

Key Words: Spirulina supplementation, type 2 diabetes, lipid profile, antioxidant capacity, inflammatory response

Introduction

The prevalence of diabetes mellitus has been rapidly increasing in Korea. Diet plays a key role in the treatment of diabetes and proper nutrition is vital to prevent diabetes complications (Park & Ahn, 2007). However, it is not an easy task to follow diabetic diet prescription and the compliance with diabetic diet recommendations is reported to be very poor (Woo *et al.*, 2006). In recent years, functional foods have appeared as new means to help maintain proper nutrition in patients with chronic diseases such as diabetes.

Spirulina (*Arthrospira platensis*) has received much attention as functional food regarding its association with cholesterol-regulatory properties, modulation of the host immune system, and antioxidant capacity (Hirata *et al.*, 2000; Qureshi *et al.*, 1995). There is increasing scientific and clinical evidences for its role in controlling chronic diseases such as diabetes (Iyer *et al.*, 2001), arthritis (Mishra *et al.*, 1998), anemia (Iyer *et al.*, 2000) and cancer (Mathew *et al.*, 1995).

Spirulina is a microscopic and filamentous cyanobacterium (blue-green alga) that has a long history of use as a food for

humans. Spirulina is a rich source of protein and vitamins, especially vitamin B₁₂, minerals, carotenoids, and phycocyanins. Its safety as food has been established through toxicological study (Salazar *et al.*, 1996).

Over the past decade, numerous studies have been conducted to evaluate the effect of spirulina supplementation on promoting health and controlling various disorders in humans (Kim & Kim, 2005; Parikh *et al.*, 2001; Rodriguez-Hernandez *et al.*, 2001). Blood lipid lowering effect of spirulina has been reported in healthy subjects (Park & Kim, 2003), patients with heart disease (Ramamoorthy & Premakumari, 1996), and diabetic patients (Mani *et al.*, 2000). Antioxidant properties of spirulina were demonstrated in a report on the inhibition of lipid peroxidation by its extract (Benedetti *et al.*, 2004), and immuno-enhancing effect was seen in mice fed spirulina-containing diet (Hayashi *et al.*, 1994).

We have also reported that spirulina supplementation to healthy elderly people resulted in significant reductions of plasma triglycerides, total and LDL-cholesterol, blood pressure, and improving the antioxidant status, as well as inflammatory status

* This work was supported by the third stage of BK21 Project in 2008 and by Seoul R&BD Program, No. 10526.

§ Corresponding Author: Wha-Young Kim, Tel. 82-2-3277-3093, Fax. 82-2-3277-2862, Email. wykim@ewha.ac.kr

and came to conclusion that it was suitable as a functional food for elderly people (Park & Kim, 2003; Park *et al.*, 2008). However, the effect of spirulina as a functional food for patients with diabetes has not been evaluated. In this study, we aimed to evaluate the effectiveness of spirulina as functional food in Korean patients with type 2 diabetes.

Subjects and Methods

Subjects and experimental protocol

The study subjects were recruited from a diabetes clinic in Seoul from September 2007 to May 2008. Current users of medications for diabetes, dyslipidemia, and inflammatory diseases and of vitamin supplements were excluded. Finally 37 subjects (20 male, 17 female) were enrolled in this study. The research protocol was approved by 'Institutional Review Board (IRB)' of Yonsei University. All subjects gave written informed consent before beginning the study.

At the first visit for intervention study, blood was drawn after a minimum of 12 h of fasting. Anthropometric and biochemical parameters and nutrient intakes were measured for baseline data. The enrolled subjects were randomly assigned into either spirulina or control group. When the subject entered the trial, the subject chose a numbered sealed envelope containing the randomized allocation to the spirulina (intervention) or control (no intervention) group.

The subjects in spirulina group received 40 pills containing 0.2 g of freeze-dried spirulina (8.0 g/day) for 12 consecutive weeks and control group was instructed not to take any functional foods or supplements. During the intervention period, both spirulina and control groups were asked to maintain their usual diets and levels of physical activity. They were also required to abstain from taking any other supplements.

The compliance for all subjects was confirmed by telephone twice a week. Anthropometric and biochemical parameters were measured before and after the intervention period for both spirulina and control groups. The spirulina was provided by Earth Spirulina Group (ES Co, Seoul, Korea) and sent to subjects every 2 weeks.

Anthropometric, hematological and dietary assessment

The subjects were individually interviewed to obtain general characteristics, life-style behavior and food consumption. Body weight, height and body composition were measured using In-body 4.0 (Biospace Co. Korea) and body mass index (BMI, kg/m²) was calculated. Waist circumference was measured by a tapeline and abdominal fat thickness was assessed by ultrasonographic measurement (General Electric logic 7. USA). The systolic and diastolic blood pressures were measured twice using an automatic blood pressure calculator (Biospace Co.

Korea) after 10 minute rest.

The daily nutrient intakes were assessed using Food Frequency Questionnaire (FFQ). Dietary intakes data were analyzed by Can-pro 2.0 software (The Korean Nutrition Society, Korea).

Serum levels of glucose, triglyceride, total-cholesterol, and HDL-cholesterol were measured using an autoanalyzer (COBAS MIRA. Roche. Switzerland). LDL-cholesterol and atherogenic index (AI) were calculated as described by Friendewald *et al.* (1972) and Lauer *et al.*, (1998), respectively [LDL-cholesterol=Total cholesterol-HDL-cholesterol-(Triglyceride / 5), Atherogenic index (AI)=(Total cholesterol-HDL-cholesterol / HDL-cholesterol)]. The analysis of insulin was performed at 'Seoul Medical Science Institute (SCL)' and Hemoglobin A1c was measured using an analyzer (HLC-723 G7, Tosoh, Japan).

The K_{ITT} value (%/min, insulin tolerance test) was used to assess insulin resistance. Insulin (Humulin[®], RI 0.11 U/kg body weight) was given intravenously after a 12 h fast. Plasma glucose was then measured at 0, 3, 6, 9, 12, and 15 min. After the plasma glucose levels were converted to natural logarithms, the slope of the reduction in plasma glucose (K_{ITT}) was calculated: K_{ITT} = 0.693/t_{1/2} × 100 (%/min) (Monzillo & Hamdy, 2003).

Inflammation and antioxidant status assessment

Serum adiponectin concentration was determined with enzyme linked immunosorbent assay (ELISA) kits (Mesdia Technology Inc., Korea) according to the manufacturer's instructions. Ten microliters of serum samples were assayed in parallel to known adiponectin recombinant concentrations. Each assay was calibrated using an adiponectin standard curve.

Serum IL-6 and TNF-α concentrations were determined by enzyme linked immunosorbent assay (ELISA) technique (Quantikine, R&D Systems Inc., USA) reading ELISA reader (Spectra Max 340, USA).

Serum malondialdehyde (MDA) level, an index of antioxidant capacity, was measured using a Lipid Peroxidation Assay kit (Oxford Biomedical Research, USA). This assay is based on the reaction of a chromogenic reagent, N-methyl-2-phenylindole (R1), with MDA at 45 °C. The reactive product produces a chromophore that has a stable violet color, the intensity of which is measured at 586 nm. MDA concentration was calculated using a MDA standard curve.

Statistical analysis

Statistical analysis was performed with the SPSS program (version 12.0). Data were presented as mean ± S.E. Chi-square test was performed to determine differences at baseline in frequencies of categorized variables between the groups and mean differences were analyzed by analysis of covariance (ANCOVA). Paired t-test was used to analyze mean differences for all measured parameters between baseline and end of intervention period. To demonstrate the association between baseline blood profiles and mean change of various parameters,

partial correlation coefficients analysis was conducted. Data within each group were analyzed by repeated measures analysis of variance to establish significant differences in treatment. The P value of less than 0.05 was considered statistically significant.

Results

There were no significant differences in baseline characteristics between spirulina and control groups such as age, sex and diabetic family history, cigarette smoking, alcohol consumption (Table 1). Also, no differences were found in anthropometric and hematological parameters and dietary intakes.

Blood profiles during the intervention period

After 12 weeks of intervention, no significant changes were observed in the plasma levels of fasting blood glucose (FBG), hemoglobin A1c, insulin, total cholesterol, LDL-cholesterol, and HDL-cholesterol in either group (Table 2). The atherogenic index, K_{ITT} , and blood pressure also were not significantly changed for both spirulina and control groups. However, plasma level of triglycerides was significantly decreased (from 125.8 mg/dl to 98.5 mg/dl, $p<0.05$) after the spirulina intervention.

Table 1. Baseline characteristics of subjects in the intervention study

Variables	Spirulina (n=19)	Control (n=18)
Age (years)	52.1 ± 2.3 ¹⁾	54.5 ± 1.5
Sex (Male/Female, %)	47.4/52.6	61.1/38.9
Duration of DM (years)	2.8 ± 4.6	2.1 ± 4.9
Cigarette smoking (yes, %)	10.5	29.4
Alcohol drinking (yes, %)	36.8	38.9
Anthropometric variables		
Weight (kg)	62.7 ± 2.2	64.9 ± 2.7
BMI (kg/m ²)	23.8 ± 0.5	23.4 ± 0.5
WHR	0.90 ± 0.01	0.90 ± 0.01
Diet intakes		
Energy (kcal/day)	1806.5 ± 111.7	1808.9 ± 114.8
Protein (g/day)	74.7 ± 5.8	79.4 ± 6.0
Fat (g/day)	46.4 ± 4.6	49.1 ± 4.7
Carbohydrate (g/day)	267.2 ± 14.5	253.7 ± 14.9
Biochemical variables		
Fasting blood glucose (mg/dl)	128.0 ± 3.8	127.8 ± 3.5
Insulin (ng/dl)	10.7 ± 0.7	9.7 ± 0.9
Total-cholesterol (mg/dl)	203.1 ± 8.1	186.9 ± 6.4
LDL-cholesterol (mg/dl)	129.4 ± 7.5	106.9 ± 6.5
HDL-cholesterol (mg/dl)	48.8 ± 3.0	52.6 ± 3.2
Triglyceride (mg/dl)	125.8 ± 14.1	110.7 ± 14.1
K_{ITT} index	2.67 ± 0.16	2.61 ± 0.20
Blood pressure		
SBP (mmHg)	130.7 ± 3.8	131.8 ± 4.0
DBP (mmHg)	84.0 ± 2.1	80.1 ± 2.5

¹⁾ Mean ± SE

BMI= Body mass index, WHR= Waist-to-hip ratio, SBP= Systolic blood pressure, DBP= Diastolic blood pressure

Table 2. Blood profiles and blood pressure of the subjects during intervention period

Variables	Spirulina (n=19)		Control (n=18)		P
	baseline	12 th week	baseline	12 th week	
Fasting blood glucose (mg/dl)	128.0 ± 3.8 ¹⁾	130.3 ± 4.1	127.8 ± 3.5	129.9 ± 7.9	0.216
HbA1c (%)	6.90 ± 0.18	7.07 ± 0.13	6.74 ± 0.13	7.21 ± 0.21	0.503
Insulin (ng/dl)	10.7 ± 0.7	9.01 ± 0.75	9.7 ± 0.9	8.52 ± 0.95	0.495
Total-cholesterol (mg/dl)	203.1 ± 8.1	203.8 ± 6.0	186.9 ± 6.4	197.2 ± 10.7	0.740
LDL-cholesterol (mg/dl)	129.4 ± 7.5	132.0 ± 5.5	106.9 ± 6.5	112.8 ± 6.6	0.599
HDL-cholesterol (mg/dl)	48.8 ± 3.0	50.18 ± 2.6	52.6 ± 3.2	53.1 ± 3.6	0.715
Triglyceride (mg/dl)	125.8 ± 14.1	98.5 ± 11.6*	110.7 ± 14.1	128.2 ± 18.1	0.022
LDL/HDL ratio	2.77 ± 0.2	2.73 ± 0.1	1.92 ± 0.1	2.10 ± 0.1	0.353
Atherogenic index	3.38 ± 0.2	3.29 ± 0.2	2.73 ± 0.2	2.92 ± 0.2	0.372
K_{ITT} index	2.67 ± 0.1	2.65 ± 0.2	2.61 ± 0.2	2.68 ± 0.2	0.602
SBP (mmHg)	130.7 ± 3.8	129.4 ± 2.7	131.8 ± 4.0	133.4 ± 4.5	0.885
DBP (mmHg)	84.0 ± 2.1	79.8 ± 2.1	80.1 ± 2.5	83.5 ± 2.7	0.021

¹⁾ Mean ± SE

P = Pr>F by repeated measured ANOVA between spirulina and control group after adjusting for sex

Asterisk = Significantly different by paired t-test between baseline and 12th week in the same intervention group, * $p<0.05$, HbA1c=Hemoglobin A1c

Table 3. Inflammation and antioxidant status of the subjects during intervention period

Variables	Spirulina (n=19)		Control (n=18)		P
	baseline	12 th week	baseline	12 th week	
TNF- α (pg/ml)	2.25 ± 0.23 ¹⁾	1.71 ± 0.13	2.05 ± 0.50	2.09 ± 0.34	0.447
IL-6 (pg/ml)	1.56 ± 0.08	0.92 ± 0.09	1.10 ± 0.09	1.31 ± 0.28	0.197
Adiponectin (μ g/ml)	5.52 ± 0.51	6.62 ± 0.68	5.77 ± 0.75	5.69 ± 0.75	0.050
MDA (μ M/L)	2.57 ± 0.24	1.85 ± 0.22**	2.02 ± 0.36	1.96 ± 0.24	0.012

¹⁾ Mean ± SE

P = Pr>F by repeated measured ANOVA between spirulina and control group after adjusting for sex

Asterisk = Significantly different by paired t-test between baseline and 12th week in the same intervention group, * $p<0.05$, ** $p<0.01$

Spirulina supplementation showed a significant lowering effect on plasma triglyceride level and diastolic blood pressure by repeated test for treatment (time x treatment interaction, $p<0.05$).

Inflammation and antioxidant status during the Intervention period

Changes of plasma levels of inflammatory cytokines and MDA during 12 weeks of intervention period are shown in Table 3. In spirulina group, the plasma level of malondialdehyde (MDA) was significantly decreased (from 2.57 μ M/L to 1.85 μ M/L, $p<0.01$) and the plasma level of adiponectin showed a tendency of an increase (from 5.52 μ g/ml to 6.62 μ g/ml, $p<0.1$). No differences were observed in the concentrations of TNF- α and IL-6 between baseline and end of 12-week intervention period. On the other hand, the plasma levels of MDA, adiponectin, TNF-

Table 4. The partial correlation coefficients between blood lipids level at baseline and changes biochemical variables (spirulina group)

Changes after intervention	Baseline	Spirulina (n=19)			Control (n=18)		
		Triglyceride (mg/dl)	Total-cholesterol (mg/dl)	LDL-cholesterol (mg/dl)	Triglyceride (mg/dl)	Total-cholesterol (mg/dl)	LDL-cholesterol (mg/dl)
Total-cholesterol (mg/dl)		-0.238	-0.787**	-0.734**	-0.051	0.266	0.307
LDL-cholesterol (mg/dl)		-0.053	-0.665**	-0.689**	0.035	-0.203	-0.376
HDL-cholesterol (mg/dl)		0.116	-0.319	-0.286	-0.024	-0.100	-0.063
Triglyceride (mg/dl)		-0.605**	0.072	0.346	-0.519	-0.267	0.030
SBP (mmHg)		-0.570*	-0.503*	-0.314	0.240	0.002	-0.093
DBP (mmHg)		-0.501*	-0.543*	-0.399	-0.051	-0.547	-0.472
TNF- α (pg/ml)		-0.108	-0.209	-0.192	0.265	0.203	0.056
IL-6 (pg/ml)		-0.099	-0.552*	-0.532*	-0.008	-0.432	-0.478
Adiponectin (μ g/ml)		0.317	0.073	-0.003	-0.399	0.221	0.581
MDA (μ M/L)		0.106	-0.382	-0.372	-0.232	0.296	0.449

Correlation coefficients after adjusting for sex

* $p < 0.05$, ** $p < 0.01$

α , and IL-6 were not changed after 12 weeks of intervention in control group. Repeated test for treatment showed significant effects of spirulina supplementation on lowering plasma MDA (time \times treatment interaction, $p < 0.05$) and on increasing adiponectin concentration (time \times treatment interaction, $p < 0.05$).

Effect of intervention according to blood lipids level at baseline

The effect of spirulina supplementation may differ whether the subjects have dyslipidemia or not before entering intervention study. Therefore, we assessed the correlations between baseline blood lipids level and changes of biochemical variables in spirulina supplemented subjects (Table 4).

The plasma level of triglyceride at baseline was negatively correlated with changes of triglyceride ($r = -0.605$, $p < 0.01$) and systolic blood pressure ($r = -0.538$, $p < 0.05$). Also, plasma level of total cholesterol at baseline was negatively correlated with changes of plasma concentrations of total cholesterol ($r = -0.787$, $p < 0.01$), LDL-cholesterol ($r = -0.665$, $p < 0.01$), and IL-6 ($r = -0.552$, $p < 0.05$), and systolic ($r = -0.527$, $p < 0.05$) and diastolic blood pressure ($r = -0.600$, $p < 0.01$). Plasma level of LDL-cholesterol at baseline showed significant negative correlations with changes of total cholesterol ($r = -0.734$, $p < 0.01$), LDL-cholesterol ($r = -0.689$, $p < 0.01$), diastolic blood pressure ($r = -0.516$, $p < 0.05$) and IL-6 ($r = -0.532$, $p < 0.05$). On the other hand, these trends were not found in control subjects. This result indicates that subjects with higher lipid concentrations before entering intervention study showed higher reduction in lipids, inflammatory cytokine levels, and blood pressure by spirulina supplementation. However, changes in insulin resistance, adiponectin concentration and antioxidant capacity were not affected by initial blood lipid levels of the subjects.

Discussion

Spirulina is reported to be effective for improving blood lipid profiles (Torres *et al.*, 1998), enhancing immune capacity, and

reducing oxidative stress (Shklar & Schwartz, 1998). Since dyslipidemia, oxidative and inflammatory stress are considered to be the contributing factors for diabetes, spirulina is the most likely candidate as functional food for management of type 2 diabetes.

Park (2007) reported that spirulina supplementation to healthy elderly people with normal fasting blood glucose (FBG) brought a significant reduction in mean FBG from 105.1 mg/dl to 100.0 mg/dl. On the contrary, the spirulina supplementation in patients with type 2 diabetes in this study did not result in a reduction in the plasma levels of FBG, hemoglobin A1c, and insulin. The subjects in this study were type 2 diabetes mellitus (DM) patients with FBG > 126 mg/dl. Therefore spirulina may not have beneficial effect on blood glucose concentration for DM patients.

Many animal and human studies have repeatedly reported the lipid-lowering effects of spirulina. Park and Kim (2003) reported that the plasma levels of triglyceride, total cholesterol, and LDL-cholesterol in Korean elderly people were significantly decreased after spirulina supplementation for 24 weeks. Also, spirulina supplementation to type 2 diabetic patients resulted in a significant decrease in plasma concentrations of triglyceride, total cholesterol and LDL-cholesterol (Iyer *et al.*, 2001). In an animal study, rats fed a 20 % water-soluble fraction of spirulina showed a significant reduction in LDL/HDL ratio (Hosoyamada *et al.*, 1991). In our study, no changes were observed in plasma concentrations of total cholesterol, LDL-cholesterol, and HDL-cholesterol after spirulina intervention, however, a significant lowering effect on plasma triglyceride concentration was shown. The less profound cholesterol lowering effect in this study may be due to baseline lipid concentration of the subjects. The cholesterol concentrations of our subjects at baseline were in normal ranges, however, the baseline lipid profile of the previous study (Park & Kim, 2003) was higher with triglyceride of 168.2 mg/dl, and total cholesterol of 231.3 mg/dl, and LDL-cholesterol of 154.6 mg/dl. Correlation analysis in this study revealed that subjects with higher initial blood levels of triglycerides and cholesterol showed a higher reduction in lipid

concentration, blood pressure and inflammatory cytokine. Therefore, spirulina supplementation was probably more effective for lowering total cholesterol in subjects with higher blood cholesterol level before intervention.

Hypotriglyceridemic and blood pressure lowering effects of spirulina have been reported. Iwata *et al.* (1990) postulated that the hypotriglyceridemic effect of spirulina might be due to its effect on the metabolism of lipoproteins. They reported that rats fed a diet containing spirulina showed a significant increase in the activity of lipoprotein lipase compared to rats fed a high fructose diet. The mechanisms of spirulina on blood pressure are not well understood. However, Guan *et al.* (2007) have proposed that the high potassium content of spirulina may have a lowering effect on blood pressure.

Oxidative stress may play an important role in the etiology of diabetic complications (Giugliano *et al.*, 1996). Kim and Kim (2005) reported that healthy elderly subjects received spirulina supplementation for 8 weeks showed improved antioxidant status as evidenced by increased total antioxidant status and decreased thiobarbituric acid reactive substance. In accordance with these studies, spirulina supplementation in this study resulted in a significant decrease in MDA level from 2.57 $\mu\text{M/L}$ to 1.85 $\mu\text{M/L}$. Also, a significant increase in plasma adiponectin concentration was observed in this study after spirulina supplementation. An increase in adiponectin concentration with a decrease in oxidative stress would play a role in the prevention of DM complication.

In conclusion, spirulina intervention brought in favorable effect on blood lipids, anti-oxidant capacity, and inflammatory response in Korean patients with type 2 diabetes. Our results also suggest that spirulina is a promising agent as a functional food for the management of diabetes. Further studies with larger sample size and longer duration are required to ascertain the mechanism of spirulina's actions on lipid profiles, immune variables, and antioxidant capacity.

Literature cited

- Benedetti S, Benvenuti F, Pagliarini S, Francoglis, Scoglio S & Canestrari F (2004). Antioxidant properties of a novel phycocyanin extract from the blue-green alga *Aphanizomenon flos-aquae*. *Life Sci* 75:2353-2362.
- Giugliano D, Ceriello A & Daolisso G (1996). Oxidative stress and diabetic vascular complications. *Diabetes Care* 3:257-267.
- Guan Y, Zhao HY, Ding XF & Zhu YY (2007). Analysis of the contents of elements in *Spirulina* from different producing areas. *Guang Pu Xue Yu Guang Pu Fen Xi* 27:1029-1031.
- Hayashi O, Katoh T & Okuwaki Y (1994). Enhancement of antibody production in mice by dietary *Spirulina platensis*. *J Nutr Sci Vitaminol* 40:431-441.
- Hirata T, Tanaka M, Ooike M, Tsunomura T & Sakaguchi M (2000). Antioxidant activities of phycocyanobilin prepared from *Spirulina platensis*. *J Appl Phycol* 12:435-439.
- Hosoyamada Y, Takai T & Kato T (1991). Effects of water-soluble and insoluble fractions of *Spirulina* on serum lipid components and glucose tolerance in rats. *Journal of Japanese Society of Nutrition and Food Science* 44:273-277.
- Iwata K, Inayama T & Kato T (1990). Effects of spirulina platensis on plasma lipoprotein lipase activity in fructose-induced hyperlipidemia in rats. *J Nutr Sci Vitaminol* 36:165-171.
- Iyer UM, Mani V, Parikh P & Sadliwala A (2000). Effect of spirulina supplementation on blood hemoglobin levels of anemic girls. *Journal of Food Science and Technology* 37:642-647.
- Iyer UM, Parikh PM & Mani U (2001). Role of spirulina in control of glycemia and lipidemia in type 2 diabetes mellitus. *J Med Food* 4:193-199.
- Kim MH & Kim WY (2005). The change of lipid metabolism and immune function caused by antioxidant material in the hypercholesterolemic elderly women in Korea. *The Korean Journal of Nutrition* 38:67-75.
- Lauer RM, Clarke WP & Lee J (1998). Factors affecting the relationship between childhood and adult cholesterol level. *Pediatrics* 82:309-318.
- Mani UV, Desai S & Iyer UM (2000). Studies on the long-term effect of spirulina supplementation on serum lipid profile and glycated proteins in NIDDM patients. *Journal of Nutraceuticals Functional and Medical Foods* 2:25-32.
- Mathew B, Sankaranarayanan R, Nair, Varghese C, Somanathan T, Amma P, Amma N & Nair M (1995). Evaluation of chemoprevention of oral cancer with *Spirulina fusiformis*. *Nutr Cancer* 24:197-202.
- Mishra M, Labhe U, Mani UV, Iyer Um & Jani A (1998). The effect of spirulina in the treatment of bronchial asthma. *J Med Food* 3:86-92.
- Monzillo LU & Hamdy O (2003). Evaluation of insulin sensitivity in clinical practice and in research settings. *Nutr Rev* 61:397-412.
- Parikh P, Mani U & Iyer U (2001). Role of spirulina in the control of glycemia and lipidemia in type 2 diabetes mellitus. *Dig Dis Sci* 4:193-199.
- Park HJ (2007). Association of MCP-1 polymorphism with cardiovascular risk factors in Korean elderly. Doctor's Thesis. Ewha Womans University of Korea
- Park HJ, Lee YJ, Ryu HK, Kim MH, Chung HW & Kim WY (2008). A randomized double-blind, placebo-controlled study to establish the effects of spirulina in elderly Koreans. *Ann Nutr Metab* 52:322-328.
- Park JS & Ahn CW (2007). Educational program for diabetic patients in Korea-Multidisciplinary intensive management. *Diabetes Res Clin Pract* 77:194-198.
- Park JY & Kim WY (2003). The effect of spirulina on lipid metabolism, antioxidant capacity and immune function in Korean elderly. *The Korean Journal of Nutrition* 36:287-297.
- Qureshi MA, Kidd MT & Ali RA (1995). *Spirulina platensis* extract enhances chicken macrophage functions after in vitro exposure. *Journal of Nutritional Immunology* 3:35-44.
- Ramamoorthy A & Premakumari S (1996). Effect of supplementation of *Spirulina* on hypercholesterolemic patients. *Journal of Food Science and Technology* 33:124-127.
- Rodriguez-Hernandez A, Ble-Castillo JL, Juarez-Oropeza MA & Diazgoya JC (2001). *Spirulina maxima* prevents fatty liver formation in CD-1 male and female mice with experimental diabetes. *Life Sci* 69:1029-1037.
- Salazar M, Chamorro G, Salazar S & Steele C (1996). Effect of *Spirulina maxima* consumption on reproductive and peri-and postnatal development in rats. *Food Chem Toxicol* 34:353-359.
- Shklar G & Schwartz J (1998). Tumor necrosis factor in experimental

- cancer regression with alpha-tocopherol, beta-carotene, canthaxanthin and algae extract. *Eur J Cancer Clin Oncol* 24:839-850.
- Torres PV, Miranda R, Paredes MC & Mascher D (1998). Spirulina maxima prevents induction of fatty liver by carbon tetrachloride in the rat. *IUBMB Life* 44:787-793.
- Woo YJ, Lee HS & Kim WY (2006). Individual diabetes nutrition education can help management for type II diabetes. *The Korean Journal of Nutrition* 39:641-648.